Alyeska Investment Group
BLRX

Alyeska Investment Group’s BioLineRX BLRX Stock Holding History

Alyeska Investment Group’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-21,662
Closed -$465K – 560
2024
Q3 		$465K Sell
21,662
-27,172
-56% -$746K ﹤0.01% 489
2024
Q2 		$1.11M Buy
+48,834
New +$1.31M 0.01% 457
2017
Q3 		– Sell
-1,466
Closed -$743K – 470
2017
Q2 		$743K Sell
1,466
-2,284
-61% -$1.17M 0.01% 421
2017
Q1 		$2.16M Buy
3,750
+2,679
+250% +$1.72M 0.02% 396
2016
Q4 		$591K Buy
1,071
+9
+0.8% +$5.59K ﹤0.01% 442
2016
Q3 		$733K Buy
1,062
+42
+4% +$22.4K 0.01% 422
2016
Q2 		$490K Buy
1,020
+21
+2% +$11.8K ﹤0.01% 403
2016
Q1 		$612K Buy
999
+258
+35% +$162K 0.01% 364
2015
Q4 		$578K Sell
741
-578
-44% -$480K 0.01% 352
2015
Q3 		$1.21M Buy
1,319
+92
+7% +$98.2K 0.01% 373
2015
Q2 		$1.96M Sell
1,227
-23
-2% -$28.5K 0.02% 353
2015
Q1 		$1.58M Buy
+1,250
New +$1.54M 0.02% 393

Other funds holding BLRX

HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
VFA
Values First Advisors Gray, Tennessee $192M AUM 24.96% 1-Year Est. Return
AWS
Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
OGF
Orin Green Financial San Diego, California $271M AUM 20.78% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
GI
Gradient Investments Arden Hills, Minnesota $7.25B AUM 20.71% 1-Year Est. Return

Alyeska Investment Group's BLRX Position: Q4 2024 in Review

Alyeska Investment Group sold out of BioLineRX (BLRX) in Q4 2024, closing a stake of 21,662 shares — an estimated $465K sold.

Alyeska Investment Group first reported a position in BLRX in Q1 2015 and held it in 12 quarters. The position peaked at $2.16M in Q1 2017. 31 funds tracked by Wall St. Rank hold BLRX as of Q4 2024.

  • Alyeska Investment Group reported no remaining BioLineRX position as of Q4 2024 after selling out during the quarter.
  • Alyeska Investment Group sold 21,662 BioLineRX shares in Q4 2024, an estimated $465K.
  • Alyeska Investment Group first reported a position in BioLineRX in Q1 2015 and held it in 12 quarters.
  • Alyeska Investment Group's BioLineRX position peaked at $2.16M in Q1 2017.
  • 31 funds tracked by Wall St. Rank held BioLineRX as of Q4 2024.

Based on Alyeska Investment Group's 13F filing for Q4 2024, filed 14 Feb 2025.